Epithelial–mesenchymal plasticity and circulating tumor cells: Travel companions to metastases

Developmental Dynamics

Volumn 247, Issue 3, 2018, Pages 432-450

  Francart, Marie Emilie ^a   Lambert, Justine ^a   Vanwynsberghe, Aline M ^a   Thompson, Erik W ^b   Bourcy, Morgane ^a   Polette, Myriam ^c   Gilles, Christine ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^c UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

Author keywords

coagulation; CTC; early metastasis; EMP; EMT

Indexed keywords

BLOOD CLOTTING; CANCER PATIENT; CELL PLASTICITY; CELL SURVIVAL; CIRCULATING TUMOR CELL; CLINICAL STUDY; CYTOSKELETON; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; IMMUNE SYSTEM; METASTASIS; MOLECULAR BIOLOGY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; PATHOLOGY; TUMOR EMBOLISM;

CELL PLASTICITY; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING;

EID: 85019766421     PISSN: 10588388     EISSN: 10970177     Source Type: Journal    
DOI: 10.1002/dvdy.24506     Document Type: Review

References (216)

1. Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, Yu M, Pely A, Engstrom A, Zhu H, Brannigan BW, Kapur R, Stott SL, Shioda T, Ramaswamy S, Ting DT, Lin CP, Toner M, Haber DA, Maheswaran S. 2014. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 158:1110–1122.
2. Aceto N, Toner M, Maheswaran S, Haber DA. 2015. En route to metastasis: circulating tumor cell clusters and epithelial-to-mesenchymal transition. Trends Cancer 1:44–52.
3. Akalay I, Janji B, Hasmim M, Noman MZ, Andre F, De Cremoux P, Bertheau P, Badoual C, Vielh P, Larsen AK, Sabbah M, Tan TZ, Keira JH, Hung NT, Thiery JP, Mami-Chouaib F, Chouaib S. 2013. Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis. Cancer Res 73:2418–2427.
4. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S. 2009. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 11:R46.
5. Alix-Panabieres C, Bartkowiak K, Pantel K. 2016. Functional studies on circulating and disseminated tumor cells in carcinoma patients. Mol Oncol 10:443–449.
6. Alix-Panabieres C, Mader S, Pantel K. 2017. Epithelial-mesenchymal plasticity in circulating tumor cells. J Mol Med (Berl) 95:133–142.
7. Alix-Panabieres C, Pantel K. 2016. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov 6:479–491.
8. Alix-Panabières C, Pantel K. 2014. Technologies for detection of circulating tumor cells: facts and vision. Lab Chip 14:57–62.
9. Alonso-Alconada L, Muinelo-Romay L, Madissoo K, Diaz-Lopez A, Krakstad C, Trovik J, Wik E, Hapangama D, Coenegrachts L, Cano A, Gil-Moreno A, Chiva L, Cueva J, Vieito M, Ortega E, Mariscal J, Colas E, Castellvi J, Cusido M, Dolcet X, Nijman HW, Bosse T, Green JA, Romano A, Reventos J, Lopez-Lopez R, Salvesen HB, Amant F, Matias-Guiu X, Moreno-Bueno G, Abal M. 2014. Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer. Mol Cancer 13:223.
10. Alpaugh ML, Tomlinson JS, Kasraeian S, Barsky SH. 2002. Cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in inflammatory breast carcinoma. Oncogene 21:3631–3643.
11. Alsuliman A, Colak D, Al-Harazi O, Fitwi H, Tulbah A, Al-Tweigeri T, Al-Alwan M, Ghebeh H. 2015. Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells. Mol Cancer 14:149.
12. Anantharaman A, Friedlander T, Lu D, Krupa R, Premasekharan G, Hough J, Edwards M, Paz R, Lindquist K, Graf R, Jendrisak A, Louw J, Dugan L, Baird S, Wang Y, Dittamore R, Paris PL. 2016. Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients. BMC Cancer 16:744.
13. Ansieau S. 2013. EMT in breast cancer stem cell generation. Cancer Lett 338:63–68.
14. Armstrong AJ, Marengo MS, Oltean S, Kemeny G, Bitting RL, Turnbull JD, Herold CI, Marcom PK, George DJ, Garcia-Blanco MA. 2011. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol.Cancer Res 9:997–1007.
15. Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V, Klein C, Saini M, Bäuerle T, Wallwiener M, Holland-Letz T, Höfner T, Sprick M, Scharpff M, Marmé F, Sinn HP, Pantel K, Weichert W, Trumpp A. 2013. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 31:539–544.
16. Balic M, Lin H, Young L, Hawes D, Giuliano A, McNamara G, Datar RH, Cote RJ. 2006. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 12:5615–5621.
17. Bao W, Qiu H, Yang T, Luo X, Zhang H, Wan X. 2013. Upregulation of TrkB promotes epithelial-mesenchymal transition and anoikis resistance in endometrial carcinoma. PLoS One 8:e70616.
18. Barbazan J, Muinelo-Romay L, Vieito M, Candamio S, Diaz-Lopez A, Cano A, Gomez-Tato A, Casares de Cal Mde L, Abal M, Lopez-Lopez R. 2014. A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer. Int J Cancer 135:2633–2643.
19. Barriere G, Fici P, Gallerani G, Fabbri F, Zoli W, Rigaud M. 2014. Circulating tumor cells and epithelial, mesenchymal and stemness markers: characterization of cell subpopulations. Ann Transl Med 2:109.
20. Barriere G, Riouallon A, Renaudie J, Tartary M, Rigaud M. 2012a. Mesenchymal and stemness circulating tumor cells in early breast cancer diagnosis. BMC Cancer 12:114.
21. Barriere G, Riouallon A, Renaudie J, Tartary M, Rigaud M. 2012b. Mesenchymal characterization: alternative to simple CTC detection in two clinical trials. Anticancer Res 32:3363–3369.
22. Bartkowiak K, Wieczorek M, Buck F, Harder S, Moldenhauer J, Effenberger KE, Pantel K, Peter-Katalinic J, Brandt BH. 2009. Two-dimensional differential gel electrophoresis of a cell line derived from a breast cancer micrometastasis revealed a stem/ progenitor cell protein profile. J Proteome Res 8:2004–2014.
23. Bednarz-Knoll N, Alix-Panabieres C, Pantel K. 2012. Plasticity of disseminating cancer cells in patients with epithelial malignancies. Cancer Metastasis Rev 31:673–687.
24. Beerling E, Seinstra D, de Wit E, Kester L, van der Velden D, Maynard C, Schafer R, van Diest P, Voest E, van Oudenaarden A, Vrisekoop N, van Rheenen J. 2016. Plasticity between epithelial and mesenchymal states unlinks EMT from metastasis-enhancing stem cell capacity. Cell Rep 14:2281–2288.
25. Bhat-Nakshatri P, Appaiah H, Ballas C, Pick-Franke P, Goulet R, Jr., Badve S, Srour EF, Nakshatri H. 2010. SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24- phenotype. BMC Cancer 10:411.
26. Biggerstaff JP, Seth N, Amirkhosravi A, Amaya M, Fogarty S, Meyer TV, Siddiqui F, Francis JL. 1999. Soluble fibrin augments platelet/tumor cell adherence in vitro and in vivo, and enhances experimental metastasis. Clin Exp Metastasis 17:723–730.
27. Biggerstaff JP, Weidow B, Dexheimer J, Warnes G, Vidosh J, Patel S, Newman M, Patel P. 2008. Soluble fibrin inhibits lymphocyte adherence and cytotoxicity against tumor cells: implications for cancer metastasis and immunotherapy. Clin Appl Thromb Hemost 14:193–202.
28. Boareto M, Jolly MK, Goldman A, Pietila M, Mani SA, Sengupta S, Ben-Jacob E, Levine H, Onuchic JN. 2016. Notch-Jagged signalling can give rise to clusters of cells exhibiting a hybrid epithelial/mesenchymal phenotype. J R Soc Interface 13:20151106.
29. Bock C, Rack B, Huober J, Andergassen U, Jeschke U, Doisneau-Sixou S. 2014. Distinct expression of cytokeratin, N-cadherin and CD133 in circulating tumor cells of metastatic breast cancer patients. Future Oncol 10:1751–1765.
30. Bockhorn M, Jain RK, Munn LL. 2007. Active versus passive mechanisms in metastasis: do cancer cells crawl into vessels, or are they pushed? Lancet Oncol 8:444–448.
31. Bonavida B, Jazirehi A, Vega MI, Huerta-Yepez S, Baritaki S. 2013. Roles each of Snail, Yin Yang 1 and RKIP in the regulation of tumor cells chemo-immuno-resistance to apoptosis. For Immunopathol Dis Therap 4:79–92.
32. Bonnomet A, Brysse A, Tachsidis A, Waltham M, Thompson EW, Polette M, Gilles C. 2010. Epithelial-to-mesenchymal transitions and circulating tumor cells. J Mammary Gland Biol Neoplasia 15:261–273.
33. Bonnomet A, Syne L, Brysse A, Feyereisen E, Thompson EW, Noel A, Foidart JM, Birembaut P, Polette M, Gilles C. 2012. A dynamic in vivo model of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast cancer. Oncogene 31:3741–3753.
34. Bourcy M, Suarez-Carmona M, Lambert J, Francart ME, Schroeder H, Delierneux C, Skrypek N, Thompson EW, Jerusalem G, Berx G, Thiry M, Blacher S, Hollier BG, Noel A, Oury C, Polette M, Gilles C. 2016. Tissue factor induced by epithelial-mesenchymal transition triggers a pro-coagulant state that drives metastasis of circulating tumor cells. Cancer Res 76:4270–4282.
35. Brabletz T. 2012. To differentiate or not — routes towards metastasis. Nat Rev Cancer 12:425–436.
36. Bulfoni M, Gerratana L, Del Ben F, Marzinotto S, Sorrentino M, Turetta M, Scoles G, Toffoletto B, Isola M, Beltrami CA, Di Loreto C, Beltrami AP, Puglisi F, Cesselli D. 2016a. In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis. Breast Cancer Res 18:30.
37. Bulfoni M, Turetta M, Del Ben F, Di Loreto C, Beltrami AP, Cesselli D. 2016b. Dissecting the heterogeneity of circulating tumor cells in metastatic breast cancer: going far beyond the needle in the haystack. Int J Mol Sci 17:pii: E1775.
38. Cao Z, Livas T, Kyprianou N. 2016. Anoikis and EMT: lethal “liaisons” during cancer progression. Crit Rev Oncog 21:155–168.
39. Cayrefourcq L, Mazard T, Joosse S, Solassol J, Ramos J, Assenat E, Schumacher U, Costes V, Maudelonde T, Pantel K, Alix-Panabieres C. 2015. Establishment and characterization of a cell line from human circulating colon cancer cells. Cancer Res 75:892–901.
40. Celia-Terrassa T, Kang Y. 2016. Distinctive properties of metastasis-initiating cells. Genes Dev 30:892–908.
41. Celia-Terrassa T, Meca-Cortes O, Mateo F, Martinez de Paz A, Rubio N, Arnal-Estape A, Ell BJ, Bermudo R, Diaz A, Guerra-Rebollo M, Lozano JJ, Estaras C, Ulloa C, Alvarez-Simon D, Mila J, Vilella R, Paciucci R, Martinez-Balbas M, de Herreros AG, Gomis RR, Kang Y, Blanco J, Fernandez PL, Thomson TM. 2012. Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. J Clin Invest 122:1849–1868.
42. Chaffer CL, San Juan BP, Lim E, Weinberg RA. 2016. EMT, cell plasticity and metastasis. Cancer Metastasis Rev 35:645–654.
43. Chen CL, Mahalingam D, Osmulski P, Jadhav RR, Wang CM, Leach RJ, Chang TC, Weitman SD, Kumar AP, Sun L, Gaczynska ME, Thompson IM, Huang TH. 2013. Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer. Prostate 73:813–826.
44. Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W, Diao L, Wang J, Roybal JD, Patel M, Ungewiss C, Peng D, Antonia S, Mediavilla-Varela M, Robertson G, Jones S, Suraokar M, Welsh JW, Erez B, Wistuba II, Chen L, Peng D, Wang S, Ullrich SE, Heymach JV, Kurie JM, Qin FX. 2014. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun 5:5241.
45. Cheung KJ, Padmanaban V, Silvestri V, Schipper K, Cohen JD, Fairchild AN, Gorin MA, Verdone JE, Pienta KJ, Bader JS, Ewald AJ. 2016. Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters. Proc Natl Acad Sci U S A 113:E854–E863.
46. Chiang SP, Cabrera RM, Segall JE. 2016. Tumor cell intravasation. Am J Physiol Cell Physiol 311:C1–C14.
47. Cho EH, Wendel M, Luttgen M, Yoshioka C, Marrinucci D, Lazar D, Schram E, Nieva J, Bazhenova L, Morgan A, Ko AH, Korn WM, Kolatkar A, Bethel K, Kuhn P. 2012. Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors. Phys Biol 9:016001.
48. Cierna Z, Mego M, Janega P, Karaba M, Minarik G, Benca J, Sedlackova T, Cingelova S, Gronesova P, Manasova D, Pindak D, Sufliarsky J, Danihel L, Reuben JM, Mardiak J. 2014. Matrix metalloproteinase 1 and circulating tumor cells in early breast cancer. BMC Cancer 14:472.
49. Cole M, Bromberg M. 2013. Tissue factor as a novel target for treatment of breast cancer. Oncologist 18:14–18.
50. De Craene B, Berx G. 2013. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 13:97–110.
51. Degen JL, Palumbo JS. 2012. Hemostatic factors, innate immunity and malignancy. Thromb Res 129(suppl 1):S1–S5.
52. Del Pozo Martin Y, Park D, Ramachandran A, Ombrato L, Calvo F, Chakravarty P, Spencer-Dene B, Derzsi S, Hill CS, Sahai E, Malanchi I. 2015. Mesenchymal cancer cell-stroma crosstalk promotes niche activation, epithelial reversion, and metastatic colonization. Cell Rep 13:2456–2469.
53. Descot A, Oskarsson T. 2013. The molecular composition of the metastatic niche. Exp Cell Res 319:1679–1686.
54. Diepenbruck M, Christofori G. 2016. Epithelial-mesenchymal transition (EMT) and metastasis: yes, no, maybe? Curr Opin Cell Biol 43:7–13.
55. Drake JM, Strohbehn G, Bair TB, Moreland JG, Henry MD. 2009. ZEB1 enhances transendothelial migration and represses the epithelial phenotype of prostate cancer cells. Mol Biol Cell 20:2207–2217.
56. Du B, Shim JS. 2016. Targeting epithelial-mesenchymal transition (EMT) to overcome drug resistance in cancer. Molecules 21:965.
57. Duda DG, Duyverman AM, Kohno M, Snuderl M, Steller EJ, Fukumura D, Jain RK. 2010. Malignant cells facilitate lung metastasis by bringing their own soil. Proc Natl Acad Sci U S A 107:21677–21682.
58. Escriva M, Peiro S, Herranz N, Villagrasa P, Dave N, Montserrat-Sentis B, Murray SA, Franci C, Gridley T, Virtanen I, Garcia de Herreros A. 2008. Repression of PTEN phosphatase by Snail1 transcriptional factor during gamma radiation-induced apoptosis. Mol Cell Biol 28:1528–1540.
59. Fabregat I, Malfettone A, Soukupova J. 2016. New insights into the crossroads between EMT and stemness in the context of cancer. J Clin Med 5:37.
60. Fidler IJ. 1973. The relationship of embolic homogeneity, number, size and viability to the incidence of experimental metastasis. Eur J Cancer 9:223–227.
61. Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong ST, Choi H, El Rayes T, Ryu S, Troeger J, Schwabe RF, Vahdat LT, Altorki NK, Mittal V, Gao D. 2015. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527:472–476.
62. Friedl P, Gilmour D. 2009. Collective cell migration in morphogenesis, regeneration and cancer. Nat Rev Mol Cell Biol 10:445–457.
63. Friedlander TW, Ngo VT, Dong H, Premasekharan G, Weinberg V, Doty S, Zhao Q, Gilbert EG, Ryan CJ, Chen WT, Paris PL. 2014. Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer. Int J Cancer 134:2284–2293.
64. Frisch SM, Schaller M, Cieply B. 2013. Mechanisms that link the oncogenic epithelial-mesenchymal transition to suppression of anoikis. J Cell Sci 126:21–29.
65. Gao D, Vela I, Sboner A, Iaquinta PJ, Karthaus WR, Gopalan A, Dowling C, Wanjala JN, Undvall EA, Arora VK, Wongvipat J, Kossai M, Ramazanoglu S, Barboza LP, Di W, Cao Z, Zhang QF, Sirota I, Ran L, MacDonald TY, Beltran H, Mosquera JM, Touijer KA, Scardino PT, Laudone VP, Curtis KR, Rathkopf DE, Morris MJ, Danila DC, Slovin SF, Solomon SB, Eastham JA, Chi P, Carver B, Rubin MA, Scher HI, Clevers H, Sawyers CL, Chen Y. 2014. Organoid cultures derived from patients with advanced prostate cancer. Cell 159:176–187.
66. Garnier D, Milsom C, Magnus N, Meehan B, Weitz J, Yu J, Rak J. 2010. Role of the tissue factor pathway in the biology of tumor initiating cells. Thromb Res 125(suppl 2):S44–S50.
67. Giampieri S, Manning C, Hooper S, Jones L, Hill CS, Sahai E. 2009. Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nat Cell Biol 11:1287–1296.
68. Giampieri S, Pinner S, Sahai E. 2010. Intravital imaging illuminates transforming growth factor beta signaling switches during metastasis. Cancer Res 70:3435–3439.
69. Gil-Bernabe AM, Ferjancic S, Tlalka M, Zhao L, Allen PD, Im JH, Watson K, Hill SA, Amirkhosravi A, Francis JL, Pollard JW, Ruf W, Muschel RJ. 2012. Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice. Blood 119:3164–3175.
70. Gil-Bernabe AM, Lucotti S, Muschel RJ. 2013. Coagulation and metastasis: what does the experimental literature tell us? Br J Haematol 162:433–441.
71. Giordano A, Gao H, Anfossi S, Cohen E, Mego M, Lee BN, Tin S, De LM, Parker CA, Alvarez RH, Valero V, Ueno NT, De PS, Mani SA, Esteva FJ, Cristofanilli M, Reuben JM. 2012. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Mol Cancer Ther 11:2526–2534.
72. Glinsky VV, Glinsky GV, Glinskii OV, Huxley VH, Turk JR, Mossine VV, Deutscher SL, Pienta KJ, Quinn TP. 2003. Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium. Cancer Res 63:3805–3811.
73. Gradilone A, Raimondi C, Nicolazzo C, Petracca A, Gandini O, Vincenzi B, Naso G, Agliano AM, Cortesi E, Gazzaniga P. 2011. Circulating tumor cells lacking cytokeratin in breast cancer: the importance of being mesenchymal. J Cell Mol Med 15:1066–1070.
74. Gunasinghe NP, Wells A, Thompson EW, Hugo HJ. 2012. Mesenchymal-epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer. Cancer Metastasis Rev 31:469–478.
75. Haddad Y, Choi W, McConkey DJ. 2009. Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines. Clin Cancer Res 15:532–542.
76. Hanssen A, Wagner J, Gorges TM, Taenzer A, Uzunoglu FG, Driemel C, Stoecklein NH, Knoefel WT, Angenendt S, Hauch S, Atanackovic D, Loges S, Riethdorf S, Pantel K, Wikman H. 2016. Characterization of different CTC subpopulations in non-small cell lung cancer. Sci Rep 6:28010.
77. Harper KL, Sosa MS, Entenberg D, Hosseini H, Cheung JF, Nobre R, Avivar-Valderas A, Nagi C, Girnius N, Davis RJ, Farias EF, Condeelis J, Klein CA, Aguirre-Ghiso JA. 2016. Mechanism of early dissemination and metastasis in Her2 + mammary cancer. Nature 540:588–592.
78. Hensler M, Vancurova I, Becht E, Palata O, Strnad P, Tesarova P, Cabinakova M, Svec D, Kubista M, Bartunkova J, Spisek R, Sojka L. 2016. Gene expression profiling of circulating tumor cells and peripheral blood mononuclear cells from breast cancer patients. Oncoimmunology 5:e1102827.
79. Hodgkinson CL, Morrow CJ, Li Y, Metcalf RL, Rothwell DG, Trapani F, Polanski R, Burt DJ, Simpson KL, Morris K, Pepper SD, Nonaka D, Greystoke A, Kelly P, Bola B, Krebs MG, Antonello J, Ayub M, Faulkner S, Priest L, Carter L, Tate C, Miller CJ, Blackhall F, Brady G, Dive C. 2014. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med 20:897–903.
80. Hou JM, Krebs M, Ward T, Sloane R, Priest L, Hughes A, Clack G, Ranson M, Blackhall F, Dive C. 2011. Circulating tumor cells as a window on metastasis biology in lung cancer. Am J Pathol 178:989–996.
81. Hou JM, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, Priest LJ, Greystoke A, Zhou C, Morris K, Ward T, Blackhall FH, Dive C. 2012. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol 30:525–532.
82. Howe EN, Cochrane DR, Richer JK. 2011. Targets of miR-200c mediate suppression of cell motility and anoikis resistance. Breast Cancer Res 13:R45.
83. Huang RY, Wong MK, Tan TZ, Kuay KT, Ng AH, Chung VY, Chu YS, Matsumura N, Lai HC, Lee YF, Sim WJ, Chai C, Pietschmann E, Mori S, Low JJ, Choolani M, Thiery JP. 2013. An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530). Cell Death Dis 4:e915.
84. Hyun KA, Koo GB, Han H, Sohn J, Choi W, Kim SI, Jung HI, Kim YS. 2016. Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer. Oncotarget 7:24677–24687.
85. Im JH, Fu W, Wang H, Bhatia SK, Hammer DA, Kowalska MA, Muschel RJ. 2004. Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res 64:8613–8619.
86. Jolly MK, Boareto M, Huang B, Jia D, Lu M, Ben-Jacob E, Onuchic JN, Levine H. 2015a. Implications of the hybrid epithelial/mesenchymal phenotype in metastasis. Front Oncol 5:155.
87. Jolly MK, Jia D, Boareto M, Mani SA, Pienta KJ, Ben-Jacob E, Levine H. 2015b. Coupling the modules of EMT and stemness: a tunable ‘stemness window’ model. Oncotarget 6:25161–25174.
88. Jolly MK, Tripathi SC, Jia D, Mooney SM, Celiktas M, Hanash SM, Mani SA, Pienta KJ, Ben-Jacob E, Levine H. 2016. Stability of the hybrid epithelial/mesenchymal phenotype. Oncotarget 7:27067–27084.
89. Joosse SA, Gorges TM, Pantel K. 2015. Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol Med 7:1–11.
90. Jordan NV, Bardia A, Wittner BS, Benes C, Ligorio M, Zheng Y, Yu M, Sundaresan TK, Licausi JA, Desai R, O'Keefe RM, Ebright RY, Boukhali M, Sil S, Onozato ML, Iafrate AJ, Kapur R, Sgroi D, Ting DT, Toner M, Ramaswamy S, Haas W, Maheswaran S, Haber DA. 2016. HER2 expression identifies dynamic functional states within circulating breast cancer cells. Nature 537:102–106.
91. Kajita M, McClinic KN, Wade PA. 2004. Aberrant expression of the transcription factors snail and slug alters the response to genotoxic stress. Mol Cell Biol 24:7559–7566.
92. Kallergi G, Agelaki S, Kalykaki A, Stournaras C, Mavroudis D, Georgoulias V. 2008. Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients. Breast Cancer Res 10:R80.
93. Kallergi G, Konstantinidis G, Markomanolaki H, Papadaki MA, Mavroudis D, Stournaras C, Georgoulias V, Agelaki S. 2013. Apoptotic circulating tumor cells in early and metastatic breast cancer patients. Mol Cancer Ther 12:1886–1895.
94. Kallergi G, Papadaki MA, Politaki E, Mavroudis D, Georgoulias V, Agelaki S. 2011. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Res 13:R59.
95. Kalluri R, Weinberg RA. 2009. The basics of epithelial-mesenchymal transition. J. Clin. Invest 119:1420–1428.
96. Kasimir-Bauer S, Hoffmann O, Wallwiener D, Kimmig R, Fehm T. 2012. Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Res 14:R15.
97. Khoo BL, Grenci G, Jing T, Lim YB, Lee SC, Thiery JP, Han J, Lim CT. 2016. Liquid biopsy and therapeutic response: circulating tumor cell cultures for evaluation of anticancer treatment. Sci Adv 2:e1600274.
98. Khoo BL, Lee SC, Kumar P, Tan TZ, Warkiani ME, Ow SG, Nandi S, Lim CT, Thiery JP. 2015. Short-term expansion of breast circulating cancer cells predicts response to anti-cancer therapy. Oncotarget 6:15578–15593.
99. Klymkowsky MW, Savagner P. 2009. Epithelial-mesenchymal transition: a cancer researcher's conceptual friend and foe. Am J Pathol 174:1588–1593.
100. Kolbl AC, Jeschke U, Andergassen U. 2016. The Significance of Epithelial-to-Mesenchymal Transition for Circulating Tumor Cells. Int J Mol Sci 17:1308.
101. Kotiyal S, Bhattacharya S. 2014. Breast cancer stem cells, EMT and therapeutic targets. Biochem Biophys Res Commun 453:112–116.
102. Krawczyk N, Meier-Stiegen F, Banys M, Neubauer H, Ruckhaeberle E, Fehm T. 2014. Expression of stem cell and epithelial-mesenchymal transition markers in circulating tumor cells of breast cancer patients. Biomed Res Int 2014:415721.
103. Krebs MG, Hou JM, Sloane R, Lancashire L, Priest L, Nonaka D, Ward TH, Backen A, Clack G, Hughes A, Ranson M, Blackhall FH, Dive C. 2012. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. J Thorac Oncol 7:306–315.
104. Krebs MG, Metcalf RL, Carter L, Brady G, Blackhall FH, Dive C. 2014. Molecular analysis of circulating tumour cells-biology and biomarkers. Nat Rev Clin Oncol 11:129–144.
105. Ksiazkiewicz M, Markiewicz A, Zaczek AJ. 2012. Epithelial-mesenchymal transition: a hallmark in metastasis formation linking circulating tumor cells and cancer stem cells. Pathobiology 79:195–208.
106. Kumar S, Park SH, Cieply B, Schupp J, Killiam E, Zhang F, Rimm DL, Frisch SM. 2011. A pathway for the control of anoikis sensitivity by E-cadherin and epithelial-to-mesenchymal transition. Mol Cell Biol 31:4036–4051.
107. Kurrey NK, Jalgaonkar SP, Joglekar AV, Ghanate AD, Chaskar PD, Doiphode RY, Bapat SA. 2009. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 27:2059–2068.
108. Labelle M, Begum S, Hynes RO. 2011. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 20:576–590.
109. Labelle M, Begum S, Hynes RO. 2014. Platelets guide the formation of early metastatic niches. Proc Natl Acad Sci U S A 111:E3053–E3061.
110. Labelle M, Hynes RO. 2012. The initial hours of metastasis: the importance of cooperative host-tumor cell interactions during hematogenous dissemination. Cancer Discov 2:1091–1099.
111. Lamouille S, Xu J, Derynck R. 2014. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 15:178–196.
112. Larson CJ, Moreno JG, Pienta KJ, Gross S, Repollet M, O'Hara S M, Russell T, Terstappen LW. 2004. Apoptosis of circulating tumor cells in prostate cancer patients. Cytometry A 62:46–53.
113. Leblanc R, Peyruchaud O. 2016. Metastasis: new functional implications of platelets and megakaryocytes. Blood 128:24–31.
114. Lecharpentier A, Vielh P, Perez-Moreno P, Planchard D, Soria JC, Farace F. 2011. Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer. Br J Cancer 105:1338–1341.
115. Lee AY. 2010. Thrombosis in cancer: an update on prevention, treatment, and survival benefits of anticoagulants. Hematology Am Soc Hematol Educ Program 2010:144–149.
116. Lee JS, Magbanua MJ, Park JW. 2016. Circulating tumor cells in breast cancer: applications in personalized medicine. Breast Cancer Res Treat 160:411–424.
117. Li J, Ai Y, Wang L, Bu P, Sharkey CC, Wu Q, Wun B, Roy S, Shen X, King MR. 2016. Targeted drug delivery to circulating tumor cells via platelet membrane-functionalized particles. Biomaterials 76:52–65.
118. Li J, King MR. 2012. Adhesion receptors as therapeutic targets for circulating tumor cells. Front Oncol 2:79.
119. Li J, Sharkey CC, Huang D, King MR. 2015a. Nanobiotechnology for the therapeutic targeting of cancer cells in blood. Cell Mol Bioeng 8:137–150.
120. Li TT, Liu H, Li FP, Hu YF, Mou TY, Lin T, Yu J, Zheng L, Li GX. 2015b. Evaluation of epithelial–mesenchymal transitioned circulating tumor cells in patients with resectable gastric cancer: relevance to therapy response. World J Gastroenterol 21:13259–13267.
121. Li YM, Xu SC, Li J, Han KQ, Pi HF, Zheng L, Zuo GH, Huang XB, Li HY, Zhao HZ, Yu ZP, Zhou Z, Liang P. 2013. Epithelial-mesenchymal transition markers expressed in circulating tumor cells in hepatocellular carcinoma patients with different stages of disease. Cell Death Dis 4:e831.
122. Lim S, Becker A, Zimmer A, Lu J, Buettner R, Kirfel J. 2013. SNAI1-mediated epithelial-mesenchymal transition confers chemoresistance and cellular plasticity by regulating genes involved in cell death and stem cell maintenance. PLoS One 8:e66558.
123. Lindsay CR, Le Moulec S, Billiot F, Loriot Y, Ngo-Camus M, Vielh P, Fizazi K, Massard C, Farace F. 2016. Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer. BMC Cancer 16:168.
124. Liotta LA, Kleinerman J, Saidel GM. 1976. The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Research 36:889–894.
125. Liu H, Zhang X, Li J, Sun B, Qian H, Yin Z. 2015. The biological and clinical importance of epithelial-mesenchymal transition in circulating tumor cells. J Cancer Res Clin Oncol 141:189–201.
126. Liu YK, Hu BS, Li ZL, He X, Li Y, Lu LG. 2016. An improved strategy to detect the epithelial-mesenchymal transition process in circulating tumor cells in hepatocellular carcinoma patients. Hepatol Int 10:640–646.
127. Lou XL, Sun J, Gong SQ, Yu XF, Gong R, Deng H. 2015. Interaction between circulating cancer cells and platelets: clinical implication. Chin J Cancer Res 27:450–460.
128. Mallini P, Lennard T, Kirby J, Meeson A. 2014. Epithelial-to-mesenchymal transition: what is the impact on breast cancer stem cells and drug resistance. Cancer Treat Rev 40:341–348.
129. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA. 2008. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704–715.
130. Mariano G, Ricciardi MR, Trisciuoglio D, Zampieri M, Ciccarone F, Guastafierro T, Calabrese R, Valentini E, Tafuri A, Del Bufalo D, Caiafa P, Reale A. 2015. PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting Snail expression. Oncotarget 6:15008–15021.
131. Markiewicz A, Ksiazkiewicz M, Welnicka-Jaskiewicz M, Seroczynska B, Skokowski J, Szade J, Zaczek AJ. 2014. Mesenchymal phenotype of CTC-enriched blood fraction and lymph node metastasis formation potential. PLoS One 9:e93901.
132. Martin OA, Anderson RL, Russell PA, Cox RA, Ivashkevich A, Swierczak A, Doherty JP, Jacobs DH, Smith J, Siva S, Daly PE, Ball DL, Martin RF, MacManus MP. 2014. Mobilization of viable tumor cells into the circulation during radiation therapy. Int J Radiat Oncol Biol Phys 88:395–403.
133. Masuda T, Hayashi N, Iguchi T, Ito S, Eguchi H, Mimori K. 2016. Clinical and biological significance of circulating tumor cells in cancer. Mol Oncol 10:408–417.
134. Matrone MA, Whipple RA, Balzer EM, Martin SS. 2010. Microtentacles tip the balance of cytoskeletal forces in circulating tumor cells. Cancer Res 70:7737–7741.
135. Mazel M, Jacot W, Pantel K, Bartkowiak K, Topart D, Cayrefourcq L, Rossille D, Maudelonde T, Fest T, Alix-Panabieres C. 2015. Frequent expression of PD-L1 on circulating breast cancer cells. Mol Oncol 9:1773–1782.
136. McInnes LM, Jacobson N, Redfern A, Dowling A, Thompson EW, Saunders CM. 2015. Clinical implications of circulating tumor cells of breast cancer patients: role of epithelial mesenchymal-plasticity. Front Oncol 5:42–42.
137. Mego M, De Giorgi U, Broglio K, Dawood S, Valero V, Andreopoulou E, Handy B, Reuben JM, Cristofanilli M. 2009. Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients. Br J Cancer 101:1813–1816.
138. Mego M, Mani SA, Lee BN, Li C, Evans KW, Cohen EN, Gao H, Jackson SA, Giordano A, Hortobagyi GN, Cristofanilli M, Lucci A, Reuben JM. 2011. Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: the effect of neoadjuvant therapy. Int J Cancer 130:808–816.
139. Milsom CC, Yu JL, Mackman N, Micallef J, Anderson GM, Guha A, Rak JW. 2008. Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis. Cancer Res 68:10068–10076.
140. Mitra A, Mishra L, Li S. 2015. EMT, CTCs and CSCs in tumor relapse and drug-resistance. Oncotarget 6:10697–10711.
141. Mladinich M, Ruan D, Chan CH. 2016. Tackling cancer stem cells via inhibition of EMT transcription factors. Stem Cells Int 2016:5285892.
142. Molnar B, Ladanyi A, Tanko L, Sreter L, Tulassay Z. 2001. Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients. Clin Cancer Res 7:4080–4085.
143. Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. 2008. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 3:e2888.
144. Mu Z, Wang C, Ye Z, Austin L, Civan J, Hyslop T, Palazzo JP, Jaslow R, Li B, Myers RE, Jiang J, Xing J, Yang H, Cristofanilli M. 2015. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer. Breast Cancer Res Treat 154:563–571.
145. Nadal R, Lorente JA, Rosell R, Serrano MJ. 2013. Relevance of molecular characterization of circulating tumor cells in breast cancer in the era of targeted therapies. Expert Rev Mol Diagn 13:295–307.
146. Nicolazzo C, Raimondi C, Mancini M, Caponnetto S, Gradilone A, Gandini O, Mastromartino M, Del Bene G, Prete A, Longo F, Cortesi E, Gazzaniga P. 2016. Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab. Sci Rep 6:31726.
147. Nieto MA, Huang RY, Jackson RA, Thiery JP. 2016. EMT: 2016. Cell 166:21–45.
148. Ning Y, Zhang W, Hanna DL, Yang D, Okazaki S, Berger MD, Miyamoto Y, Suenaga M, Schirripa M, El-Khoueiry A, Lenz HJ. 2016. Clinical relevance of EMT and stem-like gene expression in circulating tumor cells of metastatic colorectal cancer patients. Pharmacogenomics J [Epub ahead of print].
149. Ocana OH, Corcoles R, Fabra A, Moreno-Bueno G, Acloque H, Vega S, Barrallo-Gimeno A, Cano A, Nieto MA. 2012. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell 22:709–724.
150. Ock CY, Kim S, Keam B, Kim M, Kim TM, Kim JH, Jeon YK, Lee JS, Kwon SK, Hah JH, Kwon TK, Kim DW, Wu HG, Sung MW, Heo DS. 2016. PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma. Oncotarget 7:15901–15914.
151. Ombrato L, Malanchi I. 2014. The EMT universe: space between cancer cell dissemination and metastasis initiation. Crit Rev Oncog 19:349–361.
152. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA. 2008. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 68:3645–3654.
153. Ota I, Li XY, Hu Y, Weiss SJ. 2009. Induction of a MT1-MMP and MT2-MMP-dependent basement membrane transmigration program in cancer cells by Snail1. Proc Natl Acad Sci U S A 106:20318–20323.
154. Palumbo JS. 2008. Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination. Semin Thromb Hemost 34:154–160.
155. Palumbo JS, Degen JL. 2007. Mechanisms linking tumor cell-associated procoagulant function to tumor metastasis. Thromb Res 120(suppl 2):S22–S28.
156. Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL, Bugge TH. 2000. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 96:3302–3309.
157. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Hu Z, Barney KA, Degen JL. 2007. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. Blood 110:133–141.
158. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Jirouskova M, Degen JL. 2005. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 105:178–185.
159. Pantel K, Speicher MR. 2015. The biology of circulating tumor cells. Oncogene 35:1216–1224.
160. Paoletti C, Li Y, Muniz MC, Kidwell KM, Aung K, Thomas DG, Brown ME, Abramson VG, Irvin WJ, Jr., Lin NU, Liu MC, Nanda R, Nangia JR, Storniolo AM, Traina TA, Vaklavas C, Van Poznak CH, Wolff AC, Forero-Torres A, Hayes DF. 2015. Significance of circulating tumor cells in metastatic triple-negative breast cancer patients within a randomized, phase II trial: TBCRC 019. Clin Cancer Res 21:2771–2779.
161. Papadaki MA, Kallergi G, Zafeiriou Z, Manouras L, Theodoropoulos PA, Mavroudis D, Georgoulias V, Agelaki S. 2014. Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer. BMC Cancer 14:651.
162. Plaks V, Kong N, Werb Z. 2015. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? Cell Stem Cell 16:225–238.
163. Polioudaki H, Agelaki S, Chiotaki R, Politaki E, Mavroudis D, Matikas A, Georgoulias V, Theodoropoulos PA. 2015. Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer. BMC Cancer 15:399.
164. Pothula SP, Xu Z, Goldstein D, Pirola RC, Wilson JS, Apte MV. 2016. Key role of pancreatic stellate cells in pancreatic cancer. Cancer Lett 381:194–200.
165. Raimondi C, Gradilone A, Naso G, Vincenzi B, Petracca A, Nicolazzo C, Palazzo A, Saltarelli R, Spremberg F, Cortesi E, Gazzaniga P. 2011. Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res Treat 130:449–455.
166. Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK, Vonderheide RH, Leach SD, Stanger BZ. 2012. EMT and dissemination precede pancreatic tumor formation. Cell 148:349–361.
167. Roberts CM, Tran MA, Pitruzzello MC, Wen W, Loeza J, Dellinger TH, Mor G, Glackin CA. 2016. TWIST1 drives cisplatin resistance and cell survival in an ovarian cancer model, via upregulation of GAS6, L1CAM, and Akt signalling. Sci Rep 6:37652.
168. Rossi E, Basso U, Celadin R, Zilio F, Pucciarelli S, Aieta M, Barile C, Sava T, Bonciarelli G, Tumolo S, Ghiotto C, Magro C, Jirillo A, Indraccolo S, Amadori A, Zamarchi R. 2010. M30 neoepitope expression in epithelial cancer: quantification of apoptosis in circulating tumor cells by CellSearch analysis. Clin Cancer Res 16:5233–5243.
169. Rossi E, Rugge M, Facchinetti A, Pizzi M, Nardo G, Barbieri V, Manicone M, De Faveri S, Chiara Scaini M, Basso U, Amadori A, Zamarchi R. 2014. Retaining the long-survive capacity of Circulating Tumor Cells (CTCs) followed by xeno-transplantation: not only from metastatic cancer of the breast but also of prostate cancer patients. Oncoscience 1:49–56.
170. Ruf W. 2012. Tissue factor and cancer. Thromb Res 130:S84–S87.
171. Satelli A, Mitra A, Brownlee Z, Xia X, Bellister S, Overman MJ, Kopetz S, Ellis LM, Meng QH, Li S. 2014. Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression. Clin Cancer Res 21:899–907.
172. Savagner P. 2015. Epithelial-mesenchymal transitions: from cell plasticity to concept elasticity. Curr Top Dev Biol 112:273–300.
173. Schmidt JM, Panzilius E, Bartsch HS, Irmler M, Beckers J, Kari V, Linnemann JR, Dragoi D, Hirschi B, Kloos UJ, Sass S, Theis F, Kahlert S, Johnsen SA, Sotlar K, Scheel CH. 2015. Stem-cell-like properties and epithelial plasticity arise as stable traits after transient Twist1 activation. Cell Rep 10:131–139.
174. Serrano MJ, Ortega FG, Alvarez-Cubero MJ, Nadal R, Sanchez-Rovira P, Salido M, Rodriguez M, Garcia-Puche JL, Delgado-Rodriguez M, Sole F, Garcia MA, Peran M, Rosell R, Marchal JA, Lorente JA. 2014. EMT and EGFR in CTCs cytokeratin negative non-metastatic breast cancer. Oncotarget 5:7486–7497.
175. Smit MA, Geiger TR, Song JY, Gitelman I, Peeper DS. 2009. A Twist-Snail axis critical for TrkB-induced epithelial-mesenchymal transition-like transformation, anoikis resistance, and metastasis. Mol Cell Biol 29:3722–3737.
176. Spiliotaki M, Mavroudis D, Kapranou K, Markomanolaki H, Kallergi G, Koinis F, Kalbakis K, Georgoulias V, Agelaki S. 2014. Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy. Breast Cancer Res 16:485.
177. Stegner D, Dutting S, Nieswandt B. 2014. Mechanistic explanation for platelet contribution to cancer metastasis. Thromb Res 133(suppl 2):S149–S157.
178. Stott SL, Hsu CHC-H, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA, Rothenberg SM, Shah AM, Smas ME, Korir GK, Floyd FP, Gilman AJ, Lord JB, Winokur D, Springer S, Irimia D, Nagrath S, Sequist LV, Lee RJ, Isselbacher KJ, Maheswaran S, Haber DA, Toner M. 2010. Isolation of circulating tumor cells using a a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A 107:18392–18397.
179. Sullivan JP, Nahed BV, Madden MW, Oliveira SM, Springer S, Bhere D, Chi AS, Wakimoto H, Rothenberg SM, Sequist LV, Kapur R, Shah K, Iafrate AJ, Curry WT, Loeffler JS, Batchelor TT, Louis DN, Toner M, Maheswaran S, Haber DA. 2014. Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov 4:1299–1309.
180. Tesfamariam B. 2016. Involvement of platelets in tumor cell metastasis. Pharmacol Ther 157:112–119.
181. Theodoropoulos PA, Polioudaki H, Agelaki S, Kallergi G, Saridaki Z, Mavroudis D, Georgoulias V. 2010. Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett 288:99–106.
182. Thompson EW, Haviv I. 2011. The social aspects of EMT-MET plasticity. Nat Med 17:1048–1049.
183. Thompson EW, Newgreen DF, Tarin D. 2005. Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? Cancer Res 65:5991–5995.
184. Thomson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N, Iwata KK, Gibson N, Haley JD. 2005. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 65:9455–9462.
185. Tinhofer I, Saki M, Niehr F, Keilholz U, Budach V. 2014. Cancer stem cell characteristics of circulating tumor cells. Int J Radiat Biol 90:622–627.
186. Tiwari N, Gheldof A, Tatari M, Christofori G. 2012. EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol 22:194–207.
187. Todenhofer T, Hennenlotter J, Dorner N, Kuhs U, Aufderklamm S, Rausch S, Bier S, Mischinger J, Schellbach D, Hauch S, Feniuk N, Bedke J, Gakis G, Stenzl A, Schwentner C. 2016. Transcripts of circulating tumor cells detected by a breast cancer-specific platform correlate with clinical stage in bladder cancer patients. J Cancer Res Clin Oncol 142:1013–1020.
188. Toss A, Mu Z, Fernandez S, Cristofanilli M. 2014. CTC enumeration and characterization: moving toward personalized medicine. Ann Transl Med 2:108.
189. Tripathi SC, Peters HL, Taguchi A, Katayama H, Wang H, Momin A, Jolly MK, Celiktas M, Rodriguez-Canales J, Liu H, Behrens C, Wistuba II, Ben-Jacob E, Levine H, Molldrem JJ, Hanash SM, Ostrin EJ. 2016. Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome. Proc Natl Acad Sci U S A 113:E1555–E1564.
190. Tsai JH, Donaher JL, Murphy DA, Chau S, Yang J. 2012. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 22:725–736.
191. Tsai JH, Yang J. 2013. Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev 27:2192–2206.
192. Tsuji T, Ibaragi S, Hu GF. 2009. Epithelial-mesenchymal transition and cell cooperativity in metastasis. Cancer Res 69:7135–7139.
193. Tsuji T, Ibaragi S, Shima K, Hu MG, Katsurano M, Sasaki A, Hu GF. 2008. Epithelial-mesenchymal transition induced by growth suppressor p12CDK2-AP1 promotes tumor cell local invasion but suppresses distant colony growth. Cancer Res 68:10377–10386.
194. Ünlü B, Versteeg HH. 2014. Effects of tumor-expressed coagulation factors on cancer progression and venous thrombosis: is there a key factor? Thromb Res 133(suppl):S76–S84.
195. Vichalkovski A, Gresko E, Hess D, Restuccia DF, Hemmings BA. 2010. PKB/AKT phosphorylation of the transcription factor Twist-1 at Ser42 inhibits p53 activity in response to DNA damage. Oncogene 29:3554–3565.
196. Wang C, Mu Z, Chervoneva I, Austin L, Ye Z, Rossi G, Palazzo JP, Sun C, Abu-Khalaf M, Myers RE, Zhu Z, Ba Y, Li B, Hou L, Cristofanilli M, Yang H. 2017a. Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer. Breast Cancer Res Treat 161:83–94.
197. Wang H, Stoecklein NH, Lin PP, Gires O. 2017b. Circulating and disseminated tumor cells: diagnostic tools and therapeutic targets in motion. Oncotarget 8:1884–1912.
198. Wang X, Sun Q, Liu Q, Wang C, Yao R, Wang Y. 2016. CTC immune escape mediated by PD-L1. Med Hypotheses 93:138–139.
199. Watson MA, Ylagan LR, Trinkaus KM, Gillanders WE, Naughton MJ, Weilbaecher KN, Fleming TP, Aft RL. 2007. Isolation and molecular profiling of bone marrow micrometastases identifies TWIST1 as a marker of early tumor relapse in breast cancer patients. Clin Cancer Res 13:5001–5009.
200. Whipple RA, Balzer EM, Cho EH, Matrone MA, Yoon JR, Martin SS. 2008. Vimentin filaments support extension of tubulin-based microtentacles in detached breast tumor cells. Cancer Res 68:5678–5688.
201. Whipple RA, Matrone MA, Cho EH, Balzer EM, Vitolo MI, Yoon JR, Ioffe OB, Tuttle KC, Yang J, Martin SS. 2010. Epithelial-to-mesenchymal transition promotes tubulin detyrosination and microtentacles that enhance endothelial engagement. Cancer Res 70:8127–8137.
202. Williams JC, Mackman N. 2012. Tissue factor in health and disease. Front Biosci (Elite Ed) 4:358–372.
203. Willipinski-Stapelfeldt B, Riethdorf S, Assmann V, Woelfle U, Rau T, Sauter G, Heukeshoven J, Pantel K. 2005. Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res 11:8006–8014.
204. Wu S, Liu S, Liu Z, Huang J, Pu X, Li J, Yang D, Deng H, Yang N, Xu J. 2015. Classification of circulating tumor cells by epithelial-mesenchymal transition markers. PLoS One 10:e0123976.
205. Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, Fu L, Pham TQ, Soriano R, Stinson J, Seshagiri S, Modrusan Z, Lin CY, O'Neill V, Amler LC. 2005. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 11:8686–8698.
206. Ye X, Weinberg RA. 2015. Epithelial-mesenchymal plasticity: a central regulator of cancer progression. Trends Cell Biol 25:675–686.
207. Yokobori T, Iinuma H, Shimamura T, Imoto S, Sugimachi K, Ishii H, Iwatsuki M, Ota D, Ohkuma M, Iwaya T, Nishida N, Kogo R, Sudo T, Tanaka F, Shibata K, Toh H, Sato T, Barnard GF, Fukagawa T, Yamamoto S, Nakanishi H, Sasaki S, Miyano S, Watanabe T, Kuwano H, Mimori K, Pantel K, Mori M. 2013. Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res 73:2059–2069.
208. Yu M, Bardia A, Aceto N, Bersani F, Madden MW, Donaldson MC, Desai R, Zhu H, Comaills V, Zheng Z, Wittner BS, Stojanov P, Brachtel E, Sgroi D, Kapur R, Shioda T, Ting DT, Ramaswamy S, Getz G, Iafrate aJ, Benes C, Toner M, Maheswaran S, Haber Da. 2014. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 345:216–220.
209. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, Concannon KF, Donaldson MC, Sequist LV, Brachtel E, Sgroi D, Baselga J, Ramaswamy S, Toner M, Haber DA, Maheswaran S. 2013. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339:580–584.
210. Yu N, Zhou J, Cui F, Tang X. 2015. Circulating tumor cells in lung cancer: detection methods and clinical applications. Lung 193:157–171.
211. Zhang K, Jiao X, Liu X, Zhang B, Wang J, Wang Q, Tao Y, Zhang D. 2010. Knockdown of snail sensitizes pancreatic cancer cells to chemotherapeutic agents and irradiation. Int J Mol Sci 11:4891–4892.
212. Zhang L, Ridgway LD, Wetzel MD, Ngo J, Yin W, Kumar D, Goodman JC, Groves MD, Marchetti D. 2013. The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci Transl Med 5:180ra148.
213. Zhang X, Wang Q, Ling MT, Wong YC, Leung SC, Wang X. 2007. Anti-apoptotic role of TWIST and its association with Akt pathway in mediating taxol resistance in nasopharyngeal carcinoma cells. Int J Cancer 120:1891–1898.
214. Zhao R, Cai Z, Li S, Cheng Y, Gao H, Liu F, Wu S, Liu S, Dong Y, Zheng L, Zhang W, Wu X, Yao X. 2016a. Expression and clinical relevance of epithelial and mesenchymal markers in circulating tumor cells from colorectal cancer. Oncotarget 8:9293–9302.
215. Zhao XY, Li L, Wang XB, Fu RJ, Lv YP, Jin W, Meng C, Chen GQ, Huang L, Zhao KW. 2016b. Inhibition of Snail Family Transcriptional Repressor 2 (SNAI2) enhances multidrug resistance of hepatocellular carcinoma cells. PLoS One 11:e0164752.
216. Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, Wu CC, LeBleu VS, Kalluri R. 2015. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527:525–530.